SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study.
BACKGROUND
Sulfotransferase 1A1 (encoded by SULT1A1) is involved in the metabolism of procarcinogens such as heterocyclic amines and polycyclic aromatic hydrocarbons, both of which are present in tobacco smoke. We recently reported a differential effect of N-acetyltransferase (NAT) 2 genotype on the association between active and passive smoking and breast cancer. Additional investigation of a common SULT1A1 genetic polymorphism associated with reduced enzyme activity and stability might therefore provide deeper insight into the modification of breast cancer susceptibility.


METHODS
We conducted a population-based case-control study in Germany. A total of 419 patients who had developed breast cancer by age 50 years and 884 age-matched control individuals, for whom risk factor information and detailed smoking history were available, were included in the analysis. Genotyping was performed using a fluorescence-based melting curve analysis method. Multivariate logistic regression analysis was used to estimate breast cancer risk associated with the SULT1A1 Arg213His polymorphism alone and in combination with NAT2 genotype in relation to smoking.


RESULTS
The overall risk for breast cancer in women who were carriers of at least one SULT1A1*2 allele was not significantly different from that for women with the SULT1A1*1/*1 genotype (adjusted odds ratio 0.83, 95% confidence interval 0.66-1.06). Risk for breast cancer with respect to several smoking variables did not differ substantially between carriers of the *2 allele and noncarriers. However, among NAT2 fast acetylators, the odds ratio associated with passive smoking only (3.23, 95% confidence interval 1.05-9.92) was elevated in homozygous carriers of the SULT1A1*1 allele but not in carriers of the SULT1A1*2 allele (odds ratio 1.28, 95% confidence interval 0.50-3.31).


CONCLUSIONS
We found no evidence that the SULT1A1 genotype in itself modifies breast cancer risk associated with smoking in women up to age 50 years. In combination with NAT2 fast acetylator status, however, the SULT1A1*1/*1 genotype might increase breast cancer risk in women exposed to tobacco smoke.
Lilla
Carmen
C
Division of Clinical Epidemiology, German Cancer Research Center, Heidelberg, Germany. c.lilla@dkfz-heidelberg.de
Risch
Angela
A
Kropp
Silke
S
Chang-Claude
Jenny
J
D000328:Adult; D017668:Age of Onset; D015239:Arylsulfotransferase / Q000235:genetics*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012907:Smoking / Q000009:adverse effects*; D014028:Tobacco Smoke Pollution / Q000009:adverse effects*
D014028:Tobacco Smoke Pollution; D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human
Epidemiology. 1999 Nov;10(6):771-3
10535795
Biochem Pharmacol. 1999 Aug 15;58(4):605-16
10413297
Cancer Causes Control. 2000 Sep;11(8):687-95
11065005
Chem Biol Interact. 2000 Dec 1;129(1-2):141-70
11154739
Cancer Res. 2000 Dec 15;60(24):6859-63
11156380
Pharmacogenetics. 2000 Dec;10(9):789-97
11191883
Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):89-94
11219777
Prev Med. 2001 Jan;32(1):82-8
11162330
Cancer Causes Control. 2001 Jan;12(1):47-59
11227925
Pharmacogenetics. 2001 Jul;11(5):373-88
11470991
Mutat Res. 2001 Oct 1;482(1-2):27-40
11535246
Biochem Biophys Res Commun. 2002 Mar 29;292(2):402-8
11906176
Environ Mol Mutagen. 2002;39(2-3):89-95
11921174
Environ Mol Mutagen. 2002;39(2-3):184-92
11921188
Food Chem Toxicol. 2002 Aug;40(8):1063-8
12067565
Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):698-704
12163321
Am J Epidemiol. 2002 Oct 1;156(7):616-26
12244030
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):953-71
12376493
Int J Cancer. 2002 Dec 1;102(4):418-21
12402313
Breast Cancer Res Treat. 2003 Mar;78(2):217-22
12725421
Int J Cancer. 2003 Nov 20;107(4):652-7
14520706
Int J Cancer. 2003 Dec 20;107(6):878-84
14601045
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):55-68
14600802
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):270-6
14973106
Carcinogenesis. 2004 May;25(5):801-7
14729582
Am J Obstet Gynecol. 1990 Feb;162(2):502-14
2178432
J Steroid Biochem Mol Biol. 1994 Mar;48(4):369-75
8142314
Cancer Res. 1996 Apr 1;56(7):1551-5
8603401
Br J Cancer. 1996 Oct;74(8):1313-6
8883424
Biochem Biophys Res Commun. 1997 Oct 9;239(1):298-304
9345314
Bull Environ Contam Toxicol. 1998 Jan;60(1):60-7
9484557
Oncol Res. 1997;9(11-12):589-96
9563006
Cancer Causes Control. 1998 Mar;9(2):173-82
9578294
Cancer Res. 1998 Aug 1;58(15):3307-11
9699660
Biochem J. 1999 Jan 1;337 ( Pt 1):45-9
9854023
Pharmacogenetics. 2000 Mar;10(2):163-9
10762004